DDInter1570 DDInter1492
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ranolazine {u} (Compound) upregulates {v} (Gene) HIST2H2BE
HIST2H2BE {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ranolazine {u} (Compound) downregulates {v} (Gene) TPI1
TPI1 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ranolazine {u} (Compound) causes {v} (Side Effect) Leukopenia
Leukopenia {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ranolazine {u} (Compound) upregulates {v} (Gene) HIST2H2BE
HIST2H2BE {u} (Gene) is regulated by {v} (Gene) KDR
KDR {u} (Gene) is bound by {v} (Compound) Ponatinib
Ranolazine {u} (Compound) downregulates {v} (Gene) TPI1
TPI1 {u} (Gene) is regulated by {v} (Gene) RET
RET {u} (Gene) is bound by {v} (Compound) Ponatinib
Ranolazine {u} (Compound) downregulates {v} (Gene) MRPS16
MRPS16 {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ranolazine {u} (Compound) causes {v} (Side Effect) Leukopenia
Leukopenia {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ranolazine {u} (Compound) causes {v} (Side Effect) Hot flush
Hot flush {u} (Side Effect) is caused by {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ponatinib
Ranolazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Ranolazine (Compound) upregulates HIST2H2BE (Gene) and HIST2H2BE (Gene) is upregulated by Ponatinib (Compound)
Ranolazine (Compound) downregulates TPI1 (Gene) and TPI1 (Gene) is downregulated by Ponatinib (Compound)
Ranolazine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Ponatinib (Compound)
Ranolazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Ranolazine (Compound) upregulates HIST2H2BE (Gene) and HIST2H2BE (Gene) is regulated by KDR (Gene) and KDR (Gene) is bound by Ponatinib (Compound)
Ranolazine (Compound) downregulates TPI1 (Gene) and TPI1 (Gene) is regulated by RET (Gene) and RET (Gene) is bound by Ponatinib (Compound)
Ranolazine (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Ranolazine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Ranolazine (Compound) causes Hot flush (Side Effect) and Hot flush (Side Effect) is caused by Lansoprazole (Compound) and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Ponatinib